Loading clinical trials...

COMPLETEDNA

Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Hemodynamic Effects of Acute Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension: Single-center Randomized Controlled Trial

NCT04706546•University of Zurich

View on ClinicalTrials.gov

Summary

To study hemodynamic effects of Sildenafil during exercise in patients with pulmonary hypertension.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Informed consent as documented by signature (Appendix Informed Consent Form)
•PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic right-heart catheterization

Exclusion Criteria

•resting partial pressure of oxygen \<8 kilopascal at Zürich altitude on ambient air
•exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study
•inability to follow the procedures of the study
•patients who take nitrates
•other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Locations (2)

University Hospital of Zurich

Zurich, Canton of Zurich, Switzerland

UniversityHospital Zurich, Department of Pulmonology

Zurich, Switzerland

Key Dates

Start Date

February 1, 2021

Primary Completion Date

May 31, 2023

Completion Date

May 31, 2023

Last Updated

June 6, 2023

Enrollment

ACTUAL participants

Conditions

Hypertension, Pulmonary

Interventions

Hemodynamic effect of exercise under Sildenafil

OTHER

Hemodynamic effect of exercise

OTHER

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

NCT07079592

Artificial Intelligence (AI)Artificial Intelligence (AI) in Diagnosis+1 more

View study

RECRUITINGNA

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

NCT05719415

Hypertension, PulmonaryPulmonary Thromboembolisms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Inclusion Criteria

Exclusion Criteria

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Real-World Study of PADN for the Treatment of PAH

Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)